News & analysis
Times are shown in GMT+2, values are delayed by at least 15 minutes. Past performance is not a reliable indicator of future results.
Poxel SA is a biopharmaceutical company. It is focused on the development of novel treatments for metabolic diseases, including type 2 diabetes and liver diseases, such as nonalcoholic steatohepatitis (NASH). It has developed a portfolio of drug candidates, including its three most advanced candidates: Imeglimin, for the treatment of type 2 diabetes, and PXL770 and PXL065, for the treatment of NASH.Poxel SA is a biopharmaceutical company. It is developing drugs for metabolic diseases, in particular Type 2 diabetes.
Latest POXEL News